![]() ![]() There’s no additional scrutiny as to whether or not that’s correct,” he says. “A doctor can write down pancreatitis and there it is on the health-care claim. It relies on diagnoses recorded on health-care claims, which might not always be accurate. Jaime Almandoz, an endocrinologist at the University of Texas Southwestern Medical Center in Dallas, says that because clinical trials tend to exclude people who are at a higher risk of developing certain conditions, epidemiological studies can provide better insight into complications that might arise in the real world.īut the study has an important limitation, says Daniel Drucker, an endocrinologist at the University of Toronto in Canada. “What’s new is that, for all of them, we actually gave an incidence number,” says Mahyar Etminan, an epidemiologist at the University of British Columbia in Vancouver, Canada, and an author of the JAMA research. The study also found that semaglutide and liraglutide, another GLP-1 medication, were associated with an increased incidence of gastroparesis, a disorder that slows or stops the movement of food from the stomach to the intestine.Ĭlinical trials had already shown an association between GLP-1 drugs and gastrointestinal side effects, including nausea, constipation and rare cases of pancreatitis. The authors found that the incidence of pancreatitis - inflammation of the pancreas - was 4.6 times higher in people taking semaglutide than in people taking a weight-loss medication that does not mimic GLP-1. Tirzepatide, marketed as Mounjaro, was approved in 2022 to treat diabetes, but is also prescribed off-label for weight loss.Ī research letter published last week in JAMA looked at a sample of people with obesity in a large health-insurance database. Semaglutide was approved by the US Food and Drug Administration in 2017, under the name Ozempic, to treat type 2 diabetes, and later, in 2021, as Wegovy, for the treatment of obesity. The latest generation of anti-obesity drugs mimic a hormone called glucagon-like peptide 1 (GLP-1), which is associated with appetite regulation. Researchers have been looking into the gastrointestinal problems and loss of muscle mass connected with the medications and shared some findings earlier this month. ![]() But as demand for the drugs increases, there’s a growing interest in investigating their potential side effects. In clinical trials, these medications led to substantial weight loss - as much as an average of 21% of participants’ body weight - and semaglutide has also been shown to cut the risk of severe cardiovascular problems, which specialists celebrated as a groundbreaking result. The treatment of obesity has been revolutionized by new drugs such as semaglutide and tirzepatide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |